RNAC EBITDA | Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc. (RNAC) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$29.16M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$26.50M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$21.07M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$21.81M; Depreciation and amortization (m).

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$29.16M	(m)	$0.00	(m)	$272.00K*	-$21.08M*	(m)	$20.43M	(m)	(m)
2026-03-31	Reported	(m)	-$26.50M	(m)	$0.00	(m)	$27.00K	-$22.14M	(m)	$19.46M	(m)	(m)
2025-09-30	Reported	(m)	-$21.07M	(m)	$0.00	(m)	$1.29M*	-$15.60M*	(m)	$13.80M	(m)	(m)
2025-06-30	Reported	(m)	-$21.81M	(m)	$0.00	(m)	$2.60M*	-$17.52M*	(m)	$14.87M	(m)	(m)
2025-03-31	Reported	(m)	-$21.89M	(m)	$400.00K	(m)	$1.07M	-$23.11M	(m)	$14.67M	(m)	(m)
2024-09-30	Reported	(m)	-$17.57M	(m)	$0.00	(m)	$6.20M*	$13.69M*	(m)	$11.40M	(m)	(m)
2024-06-30	Reported	(m)	$13.76M	(m)	$33.27M	(m)	$1.59M*	-$14.45M*	(m)	$12.66M	(m)	(m)
2024-03-31	Reported	(m)	-$13.35M	(m)	$5.84M	(m)	$602.00K	-$15.92M	(m)	$9.74M	(m)	(m)
2023-09-30	Reported	(m)	-$13.06M	(m)	$6.55M	(m)	$0.00*	-$9.21M*	(m)	$13.00M	(m)	(m)
2023-06-30	Reported	(m)	-$18.64M	(m)	$5.25M	(m)	$12.00K*	-$9.89M*	(m)	$17.78M	(m)	(m)
2023-03-31	Reported	(m)	-$18.38M	(m)	$5.94M	(m)	$130.00K	-$8.77M	(m)	$18.62M	(m)	(m)
2022-09-30	Reported	(m)	-$1.60M	(m)	$20.71M	(m)	$436.00K*	$4.35M*	(m)	$16.54M	(m)	-$321.00K
2022-06-30	Reported	(m)	$13.86M	(m)	$39.27M	(m)	$99.00K*	-$12.27M*	(m)	$19.18M	(m)	(m)
2022-03-31	Reported	(m)	$10.77M	(m)	$34.00M	(m)	$455.00K	-$11.86M	(m)	$17.69M	(m)	(m)
2021-09-30	Reported	(m)	-$1.97M	(m)	$24.43M	(m)	$164.00K*	-$10.75M*	(m)	$20.95M	(m)	$15.83M
2021-06-30	Reported	(m)	$452.00K	(m)	$19.66M	(m)	$618.00K*	-$6.04M*	(m)	$14.46M	(m)	(m)
2021-03-31	Reported	(m)	-$7.16M	(m)	$11.05M	(m)	$25.00K	-$12.13M	(m)	$13.00M	(m)	(m)
2020-09-30	Reported	(m)	-$13.73M	(m)	$4.65M	(m)	$291.00K*	$65.64M*	(m)	$13.96M	(m)	$0.00
2020-06-30	Reported	(m)	-$16.37M	(m)	$0.00	(m)	$199.00K*	-$11.81M*	(m)	$10.73M	(m)	(m)
2020-03-31	Reported	(m)	-$18.82M	(m)	$0.00	(m)	$135.00K	-$11.70M	(m)	$14.72M	(m)	(m)
2019-09-30	Reported	(m)	-$11.79M	(m)	$0.00	(m)	$5.00K*	-$11.12M*	(m)	$8.10M	(m)	(m)
2019-06-30	Reported	(m)	-$16.23M	(m)	$13.00K	(m)	$5.00K*	-$7.20M*	(m)	$12.13M	(m)	(m)
2019-03-31	Reported	(m)	-$11.86M	(m)	$10.00K	(m)	$0.00	-$20.24M	(m)	$7.35M	(m)	(m)
2018-09-30	Reported	(m)	-$15.94M	(m)	$0.00	(m)	$60.00K*	-$16.03M*	(m)	$11.88M	(m)	(m)
2018-06-30	Reported	(m)	-$18.77M	(m)	$0.00	(m)	$264.00K*	-$16.97M*	(m)	$14.41M	(m)	(m)
2018-03-31	Reported	(m)	-$15.81M	(m)	$0.00	(m)	$192.00K	-$13.41M	(m)	$11.14M	(m)	(m)
2017-09-30	Reported	(m)	-$13.85M	(m)	$27.00K	(m)	$125.00K*	-$15.44M*	(m)	$9.50M	(m)	(m)
2017-06-30	Reported	(m)	-$15.87M	(m)	$26.00K	(m)	$401.00K*	-$8.61M*	(m)	$10.99M	(m)	(m)
2017-03-31	Reported	(m)	-$14.78M	(m)	$137.00K	(m)	$58.00K	-$15.32M	(m)	$11.04M	(m)	(m)
2016-09-30	Reported	(m)	-$7.47M	(m)	(m)	(m)	$276.00K*	-$5.47M*	(m)	$6.02M	(m)	(m)
2016-06-30	Reported	(m)	-$6.40M	(m)	(m)	(m)	$59.00K*	-$5.61M*	(m)	$6.00M	(m)	(m)
2016-03-31	Reported	(m)	-$6.94M	(m)	(m)	(m)	$143.00K	-$10.17M	(m)	$6.65M	(m)	(m)
2015-09-30	Reported	(m)	-$6.07M	(m)	(m)	(m)	$478.00K*	(m)	(m)	$5.48M	(m)	(m)
2015-06-30	Reported	(m)	-$6.32M	(m)	(m)	(m)	(m)	(m)	(m)	$5.31M	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$143.41M	(m)	$400.00K	(m)	$5.45M	-$73.94M	(m)	$58.03M	(m)	-$9.19M
2024-12-31	Reported	(m)	-$43.90M	(m)	$38.27M	(m)	$9.09M	-$23.67M	(m)	$45.10M	(m)	$287.00K
2023-12-31	Reported	(m)	-$86.42M	(m)	$26.00M	(m)	$206.00K	-$51.16M	(m)	$71.26M	(m)	-$19.00M
2022-12-31	Reported	(m)	$14.54M	(m)	$110.78M	(m)	$1.20M	-$31.63M	(m)	$72.38M	(m)	-$609.00K
2021-12-31	Reported	(m)	-$4.60M	(m)	$85.08M	(m)	$1.08M	-$60.38M	(m)	$68.74M	(m)	$15.97M
2020-12-31	Reported	(m)	-$56.82M	(m)	$16.60M	(m)	$815.00K	$34.88M	(m)	$54.51M	(m)	$0.00
2019-12-31	Reported	(m)	-$52.45M	(m)	$6.68M	(m)	$47.00K	-$51.44M	(m)	$42.74M	(m)	$0.00
2018-12-31	Reported	(m)	-$65.02M	(m)	$903.00K	(m)	$884.00K	-$59.16M	(m)	$47.69M	(m)	(m)
2017-12-31	Reported	(m)	-$63.78M	(m)	$207.00K	(m)	$733.00K	-$52.03M	(m)	$45.16M	(m)	(m)
2016-12-31	Reported	(m)	-$34.67M	(m)	$8.08M	(m)	$586.00K	-$19.76M	(m)	$29.70M	(m)	(m)
2015-12-31	Reported	(m)	-$25.30M	(m)	(m)	(m)	$1.16M	-$22.46M	(m)	$22.98M	(m)	(m)
2014-12-31	Reported	(m)	-$15.40M	(m)	(m)	(m)	$227.00K	(m)	(m)	$10.49M	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Keros Therapeutics, Inc. (KROS)	United States	$0.229B	-2.55
SIGA TECHNOLOGIES INC (SIGA)	United States	$0.234B	-93.33
NATURES SUNSHINE PRODUCTS INC (NATR)	United States	$0.228B	20.51
Sionna Therapeutics, Inc. (SION)	United States	$0.236B	-20.37
Camp4 Therapeutics Corp (CAMP)	United States	$0.240B	-2.12
Whitehawk Therapeutics, Inc. (WHWK)	United States	$0.221B
MACROGENICS INC (MGNX)	United States	$0.242B	-20.11
Cue Biopharma, Inc. (CUE)	United States	$0.243B	-1.01
Entrada Therapeutics, Inc. (TRDA)	United States	$0.243B	-1.73
Eledon Pharmaceuticals, Inc. (ELDN)	United States	$0.219B	-3.23